Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click on 'Find out more' to see our Cookie statement.

It is estimated that drug-resistant infections could cause 10 million deaths each year by 2050 and an annual economic cost of £69 trillion. Two major initiatives in MPLS are working to tackle the problems of antimicrobial resistance (AMR).

A generic picture of bacteria

The Ineos Oxford Institute for Antimicrobial Research (IOI) is a new biomedical discovery institute established to lead the science, provide the evidence, and educate the public in ways that support global transformational change to tackle antimicrobial resistance. Visit the Ineos Oxford Institute website for more information.

'Beyond Antibiotics' is a major new collaborative programme that started in October 2021, funded by the EPSRC and led by Professor Eleanor Stride. The primary focus is the development of new technology to enable: better characterisation of bacterial infections, rapid point-of-care diagnostics, high-throughput testing of new therapies, alternatives to antibiotics and infection prevention strategies. Read more about 'Beyond Antibiotics'.